Medical device and MedTech insights, news, tips and more

FDA Warning Letter Issued to Zimmer Biomet’s Indiana Manufacturing Site

August 28, 2018


Zimmer Biomet received a warning letter from the FDA about quality violations found at a plant in Warsaw, Indiana. The agency had flagged the issues after a 2016 inspection of the site, but found in a re-inspection earlier this year that the company’s resolution was not up to par.

The FDA inspected Zimmer Biomet’s North Campus manufacturing site in Warsaw in the fall of 2016, serving up a 58-page Form 483 that listed 14 violations. The devicemaker responded in kind with its own lengthy document detailing how it would address the issues. But those efforts appear to have fallen short, as the FDA issued a second Form 483 with 11 observations after its re-inspection in April.

The letter, disclosed Friday in an SEC filing, regarded “observed non-conformities with current good manufacturing practice requirements of the Quality System regulation” at the company’s North Campus facility.

“While the Warning Letter acknowledges our quality remediation plan and actions we’ve already taken to address the FDA’s inspectional observations, it notes violations that require additional action or explanation,” Zimmer Biomet said in the SEC filing.

Zimmer Biomet is working on a response to the letter and plans to send it within 15 business days of receipt. The company expects to meet with the FDA to discuss proposed corrections after it’s sent its response.

That said, the warning letter does not require Zimmer Biomet to pull any products from the market, nor does it restrict the production or shipment of devices from the North Campus plant. It doesn’t affect the company’s ability to seek 510(k) clearance for devices, but premarket approval applications will be on hold until all of the problems have been corrected. While Zimmer Biomet doesn’t currently have any PMA applications before the FDA, future applications could be delayed if the issue drags on.

Read More at the Source: FDA warns Zimmer Biomet about Indiana manufacturing site | FierceBiotech

By: Amirah Al Idrus

A Speciality Recruiting Firm Exclusively Servicing The Medical Device Industry

Legacy MedSearch has more than 30 years of combined experience recruiting in the medical device industry. We pride ourselves on our professionalism and ability to communicate quickly and honestly with all parties in the hiring process. Our clients include both blue-chip companies and innovative startups within the MedTech space. Over the past 10 years, we have built one of the strongest networks of device professionals ranging from sales, marketing, research & , quality & regulatory, project management, field service, and clinical affairs.

We offer a variety of different solutions for hiring managers depending on the scope and scale of each individual search. We craft a personalized solution for each client and position with a focus on attracting the best possible talent in the shortest possible time frame.

Are you hiring?
Contact us to discuss partnering with Legacy MedSearch on your position.

More insights

March 7, 2024
FDA Clears Dexcom’s First Over-the-Counter Continuous Glucose Monitor
Learn More
March 1, 2024
FDA greenlights Boston Scientific’s Novel Drug-Coated Balloon for Coronary In-Stent Restenosis
Learn More
February 21, 2024
Sparrow BioAcoustics Launches Software That Turns a Smartphone into a Stethoscope 
Learn More

Begin your legacy now. We are your medtech and medical device talent advisory firm.